Meridian Bioscience (VIVO) Stock Price

Meridian Bioscience Price

NASDAQ·CLOSED
5.23USD+0.62 (+12.60 %)
Market closed

Over the last 19 years Meridian Bioscience grew revenue by 8.9% annually, reaching 333.02 M USD. Earnings per share have grown at 8.4% per year over the last 19 years. For Meridian Bioscience, the net margin of 12.7% is up versus 11.1% a few years ago. At today's price the dividend yield works out to roughly 2.39%. The payout ratio is around 22% of earnings. The stock trades about 332% above its 52-week low.

Meridian Bioscience stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Meridian Bioscience over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Meridian Bioscience stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Meridian Bioscience's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Meridian Bioscience Stock Price History
DateMeridian Bioscience Price
7/10/20265.23 USD
7/9/20264.61 USD
7/8/20264.36 USD
7/7/20264.46 USD
7/6/20264.66 USD
7/2/20264.68 USD
7/1/20264.96 USD
6/30/20265.17 USD
6/29/20265.54 USD
6/26/20265.77 USD
6/25/20265.61 USD
6/24/20265.52 USD
6/23/20265.60 USD
6/22/20265.98 USD
6/18/20265.48 USD
6/17/20265.69 USD
6/16/20265.63 USD
6/15/20265.05 USD
6/12/20264.78 USD
6/11/20264.70 USD
6/10/20265.18 USD
6/9/20264.76 USD
6/8/20264.77 USD
6/5/20264.82 USD
6/4/20265.61 USD
6/3/20266.11 USD
6/2/20266.59 USD
6/1/20266.10 USD
5/29/20265.61 USD
5/28/20264.87 USD
5/27/20264.83 USD
5/26/20264.36 USD
5/22/20264.70 USD
5/21/20264.96 USD
5/20/20264.51 USD
5/19/20264.61 USD
5/18/20264.82 USD
5/15/20264.54 USD
5/14/20264.93 USD
5/13/20264.23 USD
5/12/20263.13 USD
5/11/20263.22 USD
5/8/20263.02 USD
5/7/20263.01 USD
5/6/20263.11 USD
5/5/20263.31 USD
5/4/20262.91 USD
5/1/20263.19 USD
4/30/20263.32 USD
4/29/20263.09 USD
4/28/20263.14 USD
4/27/20263.40 USD
4/24/20263.48 USD
4/23/20263.49 USD
4/22/20262.99 USD
4/21/20262.72 USD
4/20/20263.11 USD
4/17/20263.20 USD
4/16/20262.82 USD
4/15/20262.67 USD
4/14/20262.68 USD
4/13/20262.55 USD
4/10/20262.40 USD
4/9/20262.43 USD
4/8/20262.33 USD
4/7/20262.40 USD
4/6/20262.13 USD
4/2/20262.10 USD
4/1/20262.08 USD
3/31/20262.30 USD
3/30/20262.25 USD
3/27/20262.52 USD
3/26/20262.68 USD
3/25/20262.86 USD
3/24/20262.16 USD
3/23/20262.34 USD
3/20/20262.24 USD
3/19/20262.37 USD
3/18/20262.44 USD
3/17/20262.06 USD
3/16/20261.89 USD
3/13/20262.07 USD
3/12/20261.87 USD
3/11/20261.96 USD
3/10/20261.94 USD
3/9/20261.88 USD
3/6/20262.00 USD
3/5/20262.08 USD
3/4/20262.14 USD
3/3/20262.16 USD
3/2/20262.35 USD
2/27/20262.36 USD
2/26/20262.38 USD
2/25/20262.70 USD
2/24/20262.61 USD
2/23/20262.57 USD
2/20/20262.37 USD
2/19/20262.45 USD
2/18/20262.83 USD
2/17/20262.44 USD
2/13/20262.11 USD
2/12/20261.42 USD
2/11/20261.32 USD
2/10/20261.34 USD
2/9/20261.42 USD
2/6/20261.44 USD
2/5/20261.21 USD
2/4/20261.63 USD
2/3/20261.72 USD
2/2/20261.79 USD
1/30/20262.06 USD
1/29/20262.06 USD
1/28/20262.23 USD
1/27/20262.25 USD
1/26/20262.24 USD
1/23/20262.29 USD
1/22/20262.38 USD
1/21/20262.36 USD
1/20/20262.32 USD
1/16/20262.60 USD
1/15/20262.72 USD
1/14/20262.98 USD
1/13/20262.72 USD
1/12/20262.69 USD
1/9/20262.54 USD
1/8/20262.56 USD
1/7/20262.51 USD
1/6/20262.66 USD
1/5/20262.71 USD
1/2/20262.45 USD
12/31/20252.27 USD
12/30/20252.36 USD
12/29/20252.66 USD
12/26/20252.44 USD
12/24/20252.36 USD
12/23/20252.38 USD
12/22/20252.52 USD
12/19/20252.69 USD
12/18/20252.86 USD
12/17/20252.83 USD
12/16/20253.20 USD
12/15/20252.62 USD
12/12/20252.88 USD
12/11/20252.54 USD
12/10/20252.66 USD
12/9/20252.75 USD
12/8/20252.54 USD
12/5/20252.50 USD
12/4/20252.66 USD
12/3/20252.63 USD
12/2/20252.51 USD
12/1/20252.36 USD
11/28/20252.63 USD
11/26/20252.54 USD
11/25/20252.45 USD
11/24/20252.43 USD
11/21/20252.26 USD
11/20/20252.08 USD
11/19/20252.29 USD
11/18/20252.58 USD
11/17/20252.54 USD
11/14/20253.08 USD
11/13/20253.17 USD
11/12/20253.37 USD
11/11/20253.10 USD
11/10/20253.59 USD
11/7/20253.21 USD
11/6/20253.17 USD
11/5/20253.08 USD
11/4/20253.14 USD
11/3/20253.50 USD
10/31/20252.95 USD
10/30/20254.54 USD
10/29/20254.71 USD
10/28/20254.71 USD
10/27/20254.86 USD
10/24/20254.92 USD
10/23/20254.58 USD
10/22/20254.23 USD
10/21/20254.60 USD
10/20/20254.45 USD
10/17/20254.37 USD
10/16/20254.25 USD
10/15/20254.38 USD
10/14/20254.61 USD
10/13/20254.76 USD
10/10/20254.67 USD
10/9/20254.87 USD
10/8/20255.09 USD
10/7/20255.19 USD
10/6/20255.50 USD
10/3/20255.41 USD
10/2/20255.62 USD
10/1/20255.13 USD
9/30/20254.50 USD
9/29/20254.76 USD
9/26/20254.68 USD
9/25/20254.91 USD
9/24/20255.05 USD
9/23/20254.82 USD
9/22/20254.94 USD
9/19/20254.83 USD
9/18/20255.06 USD
9/17/20254.84 USD
9/16/20254.97 USD
9/15/20254.96 USD
9/12/20255.11 USD
9/11/20255.00 USD
9/10/20255.07 USD
9/9/20255.38 USD
9/8/20254.97 USD
9/5/20254.80 USD
9/4/20254.81 USD
9/3/20254.90 USD
9/2/20254.81 USD
8/29/20255.16 USD
8/28/20255.76 USD
8/27/20255.62 USD
8/26/20256.24 USD
8/25/20255.73 USD
8/22/20256.05 USD
8/21/20255.45 USD
8/20/20255.51 USD
8/19/20255.35 USD
8/18/20256.02 USD
8/15/20256.33 USD
8/14/20255.71 USD
8/13/20255.88 USD
8/12/20256.34 USD
8/11/20255.94 USD
8/8/20255.10 USD
8/7/20253.86 USD
8/6/20253.66 USD
8/5/20253.76 USD
8/4/20253.92 USD
8/1/20253.91 USD
7/31/20254.22 USD
7/30/20254.17 USD
7/29/20254.04 USD
7/28/20254.59 USD
7/25/20254.88 USD
7/24/20255.59 USD
7/23/20255.80 USD
7/22/20256.85 USD
7/21/20256.44 USD
7/18/20256.87 USD
7/17/20256.72 USD
7/16/20256.18 USD
7/15/20255.25 USD
7/14/20255.43 USD
Access this data via the Eulerpool API
Get Free API Key

Meridian Bioscience Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2018
213.60 M USD
44.70 M USD
23.80 M USD
Jan 1, 2019
201.00 M USD
38.90 M USD
24.40 M USD
Jan 1, 2020
253.70 M USD
68.00 M USD
46.20 M USD
Jan 1, 2021
317.90 M USD
101.83 M USD
71.41 M USD
Jan 1, 2022
333.02 M USD
75.60 M USD
42.46 M USD
Jan 1, 2023 (e)
294.11 M USD
46.97 M USD
37.34 M USD
Jan 1, 2024 (e)
302.36 M USD
32.45 M USD
26.22 M USD
Jan 1, 2025 (e)
300.53 M USD
22.86 M USD
18.78 M USD

Meridian Bioscience Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 12, 2026, 10:21 PM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
20102011201220132014201520162017201820192020202120222023e2024e2025e
143.00158.00172.00188.00188.00194.00196.00200.00213.00201.00253.00317.00333.00294.00302.00300.00
-3.3810.498.869.30–3.191.032.046.50-5.6325.8725.305.05-11.712.72-0.66
61.5462.0363.3764.3662.2362.3764.8062.0061.5058.7161.6663.4156.4656.4656.4656.46
88.0098.00109.00121.00117.00121.00127.00124.00131.00118.00156.00201.00188.00165.98170.50169.37
26.0026.0033.0038.0034.0035.0032.0021.0023.0024.0046.0071.0042.0037.0026.0018.00
-18.75–26.9215.15-10.532.94-8.57-34.389.524.3591.6754.35-40.85-11.90-29.73-30.77
41.1041.4041.6041.9041.9042.0042.4042.6042.8042.9043.2044.0144.3844.3844.3844.38
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Meridian Bioscience generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Meridian Bioscience retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Meridian Bioscience's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Meridian Bioscience has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Meridian Bioscience's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Meridian Bioscience stock margins

The Meridian Bioscience margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Meridian Bioscience. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Meridian Bioscience.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2018
61.33 %
20.93 %
11.14 %
Jan 1, 2019
59.05 %
19.35 %
12.14 %
Jan 1, 2020
61.57 %
26.80 %
18.21 %
Jan 1, 2021
63.27 %
32.03 %
22.46 %
Jan 1, 2022
56.56 %
22.70 %
12.75 %
Jan 1, 2023 (e)
56.56 %
15.97 %
12.70 %
Jan 1, 2024 (e)
56.56 %
10.73 %
8.67 %
Jan 1, 2025 (e)
56.56 %
7.61 %
6.25 %

Meridian Bioscience Stock Revenue, EBIT, Earnings per Share

The Meridian Bioscience earnings per share therefore indicates how much revenue Meridian Bioscience has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2018
4.99 USD
1.04 USD
0.56 USD
Jan 1, 2019
4.69 USD
0.91 USD
0.57 USD
Jan 1, 2020
5.87 USD
1.57 USD
1.07 USD
Jan 1, 2021
7.22 USD
2.31 USD
1.62 USD
Jan 1, 2022
7.50 USD
1.70 USD
0.96 USD
Jan 1, 2023 (e)
6.63 USD
1.06 USD
0.84 USD
Jan 1, 2024 (e)
6.81 USD
0.73 USD
0.59 USD
Jan 1, 2025 (e)
6.77 USD
0.52 USD
0.42 USD

Meridian Bioscience business model & stock analysis

Meridian Bioscience Inc. is a global company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. The company was founded in 1976 by William J. Motto and initially focused on the development of enzyme immunoassays (EIA). Over the years, the company has grown and diversified its product offerings, becoming a leading provider of diagnostic test kits for acute and chronic medical conditions, infectious diseases, gastrointestinal infections, and virology. The company's success is attributed to its diverse range of test kits in various medical areas, including immunology, infectious diseases, sexually transmitted diseases, gastroenterology, and virology. Additionally, Meridian Bioscience Inc. stays up-to-date with the latest technological advancements in biotechnology to ensure the fast and effective performance of its tests. The company operates globally, collaborating with universities, research institutions, government agencies, and distributors to ensure the worldwide distribution and marketing of its products. In summary, Meridian Bioscience Inc. is an innovative company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. Its wide range of products, including immunology products, infectious disease diagnostics, sexually transmitted disease test kits, gastroenterology, virology, and molecular diagnostics, coupled with advanced technologies, provides fast, accurate, and reliable diagnostic support.

Meridian Bioscience SWOT Analysis

Strengths

Meridian Bioscience Inc has a strong reputation in the healthcare industry, particularly in the field of diagnostics and testing kits. The company's advanced technology and extensive product portfolio give it a competitive edge.

Meridian Bioscience Inc has a solid financial position with stable revenues and profits. Its strong financial standing allows the company to invest in research and development, innovate its product offerings, and expand its market presence.

Weaknesses

Despite its strong reputation and financial position, Meridian Bioscience Inc faces certain weaknesses. The company relies heavily on a few key customers for a significant portion of its revenue, which creates a dependency and increases the risk of revenue fluctuations.

Another weakness is the limited geographical presence of Meridian Bioscience Inc. The company primarily operates within the United States, which restricts its market reach and exposes it to potential risks associated with regional economic downturns or regulatory changes.

Opportunities

The increasing global demand for diagnostics and healthcare products presents significant opportunities for Meridian Bioscience Inc. The company can expand its market presence by entering new geographical regions and tapping into emerging markets with a growing need for healthcare solutions.

Furthermore, advancements in technology and the ongoing COVID-19 pandemic have accelerated the importance of rapid testing and diagnostics. Meridian Bioscience Inc can leverage these opportunities to develop and market innovative solutions that address the evolving healthcare landscape.

Threats

Meridian Bioscience Inc faces competition from other established players in the healthcare industry. The presence of larger competitors with greater resources and market presence poses a threat to the company's market share and growth prospects.

Additionally, regulatory challenges and changing government policies can create uncertainties for Meridian Bioscience Inc. Compliance with evolving regulations and adherence to quality standards require continuous monitoring and can impact the company's operations and profitability.

Meridian Bioscience Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Meridian Bioscience historical P/E ratio, EBIT multiple, and P/S ratio

Meridian Bioscience annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Meridian Bioscience shares outstanding

The number of shares of Meridian Bioscience was 44.38 M in 2025. This indicates how many shares Meridian Bioscience is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2018
42.80 M Stocks
Jan 1, 2019
42.90 M Stocks
Jan 1, 2020
43.20 M Stocks
Jan 1, 2021
44.01 M Stocks
Jan 1, 2022
44.38 M Stocks
Jan 1, 2023 (e)
44.38 M Stocks
Jan 1, 2024 (e)
44.38 M Stocks
Jan 1, 2025 (e)
44.38 M Stocks

Meridian Bioscience stock splits

In Meridian Bioscience's history, there have been no stock splits.

Meridian Bioscience Dividend History

20 years of dividend payments

YearAnnual DividendYoY ChangePayments
20190.13USD↓ 75.0%1×
20180.50USD 0.0%4×
20170.50USD↓ 37.5%4×
20160.80USD 0.0%4×
20150.80USD 0.0%4×
20140.80USD↑ 5.3%4×
20130.76USD↓ 20.0%4×
20120.95USD↑ 25.0%5×
20110.76USD 0.0%4×
20100.76USD↑ 11.8%4×

Meridian Bioscience dividend payout ratio

In 2025, Meridian Bioscience had a payout ratio of 56.51%. The payout ratio indicates the percentage of the company's profits that Meridian Bioscience distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2018
90.91 %
Jan 1, 2019
21.93 %
Jan 1, 2020
70.29 %
Jan 1, 2021
61.04 %
Jan 1, 2022
51.09 %
Jan 1, 2023 (e)
60.81 %
Jan 1, 2024 (e)
57.65 %
Jan 1, 2025 (e)
56.51 %
Price targets and forecasts for Meridian Bioscience are not yet available.

Meridian Bioscience Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
11/20/20230.21USD74.59 MUSD2023 Q4
8/3/20230.21USD77.95 MUSD2023 Q3
5/4/20230.22USD76.33 MUSD2023 Q2
2/2/20230.20USD72.52 MUSD2023 Q1
11/29/20220.15USD68.44 MUSD2022 Q4
8/5/20220.16USD67.82 MUSD2022 Q3
5/6/20220.48USD101.03 MUSD2022 Q2
2/4/20220.26USD71.35 MUSD2022 Q1
11/12/20210.21USD69.42 MUSD2021 Q4
8/6/20210.31USD78.38 MUSD2021 Q3
...

Meridian Bioscience shareholder structure

% Name
15.21430%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
11.08761%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
4.96770%
Magnetar Capital Partners LP
Magnetar Capital Partners LP
4.42927%
Renaissance Technologies LLC
Renaissance Technologies LLC
4.30630%
Impactive Capital LP
Impactive Capital LP
4.06338%
Dimensional Fund Advisors, L.P.
Dimensional Fund Advisors, L.P.
...

Meridian Bioscience Executives and Management Board

JK

Mr. John Kenny

(54)

Chief Executive Officer, Director · since 2017

Compensation4.60 M USD
LW

Dr. Lourdes Weltzien

(57)

Executive Vice President - Life Science

Compensation1.23 M USD
TL

Mr. Tony Serafini - Lamanna

(59)

Executive Vice President - Diagnostics

Compensation1.20 M USD
AK

Mr. Andrew Kitzmiller

(43)

Chief Financial Officer, Executive Vice President, Director · since 2022

Compensation882,896.00 USD
JS

Ms. Julie Smith

(54)

Senior Vice President, Principal Accounting Officer, Controller

Compensation786,416.00 USD

Meridian Bioscience Supply Chain

Meridian Bioscience Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
3 companies
#Name1M3M6M1Y2YTrend
1
DiaSorin SpA
Supplier
0.76
0.50
-0.78
-0.77
-0.47
2
Eiken Chemical
Supplier
0.28
-0.14
-0.86
-0.68
-0.26
3
Bruker
Supplier
0.91
-0.25
-0.78
-0.74
0.09

Frequently asked questions about Meridian Bioscience

The business model of Meridian Bioscience Inc revolves around manufacturing and distributing diagnostic products for the healthcare industry. With a focus on infectious disease testing, the company provides a range of products including molecular and immunoassay tests, as well as reagents and related equipment. Meridian Bioscience Inc aims to develop innovative solutions for quick and accurate diagnosis, helping healthcare professionals worldwide make informed decisions. Through its expertise and continual investment in research and development, the company strives to improve patient outcomes and contribute to the overall public health. Meridian Bioscience Inc's commitment to quality and customer satisfaction is evident in their comprehensive portfolio of diagnostic solutions.

All fundamentals and in-depth analysis of Meridian Bioscience

Our stock analysis for Meridian Bioscience stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Meridian Bioscience. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Meridian Bioscience Stock
Meridian Bioscience Revenue→
Meridian Bioscience Stock
Meridian Bioscience Net Income→
Meridian Bioscience Stock
Meridian Bioscience P/E→
Meridian Bioscience Stock
Meridian Bioscience P/S→
Meridian Bioscience Stock
Meridian Bioscience EBIT→
Meridian Bioscience Stock
Meridian Bioscience Dividend→
Meridian Bioscience Stock
Meridian Bioscience Directors Dealings→
Meridian Bioscience Stock
Meridian Bioscience Stocks→
Meridian Bioscience Stock
Meridian Bioscience Market capitalization→
Meridian Bioscience Stock
Meridian Bioscience Debt→
Meridian Bioscience Stock
Meridian Bioscience Liabilities→
Meridian Bioscience Stock
Meridian Bioscience Equity→
Meridian Bioscience Stock
Meridian Bioscience AAQS→
Meridian Bioscience Stock
Meridian Bioscience Employees→
Meridian Bioscience Stock
Meridian Bioscience ROE→
Meridian Bioscience Stock
Meridian Bioscience ROA→
Meridian Bioscience Stock
Meridian Bioscience ROCE→
Meridian Bioscience Stock
Meridian Bioscience News→
Meridian Bioscience Stock
Meridian Bioscience Analyst Price Targets→

Health Stocks

Merit Medical SystemsMereo BioPharma GroupMesa LaboratoriesMerdury BiopharmaceuticalMesoblastMerck Tbk PTMesoblastMerck KGaAMetabiomed CoMerck & CoMetacare CoMerchavia Holdings and InvestmentsAll Stocks A–Z →